This trial is evaluating whether Pimasertib will improve 5 primary outcomes and 5 secondary outcomes in patients with Cancer. Measurement will happen over the course of At 4 weeks after first administration of treatment.
This trial requires 36 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pimasertib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Our main objective was not to prove the lack of discovery, but to make it obvious that the advancement of research in oncology is still very much ongoing.
There is no cure for cancer; treatment is tailored to address the particular disease or tumors that are present. Patients and clinicians should be aware of the most common treatments for cancer and the related comorbidities.
Some of the most common cancers manifest through symptoms. The presentation can include increased weight, loss of appetite, fever, jaundice, and a red, swollen, or itchy throat. If the cancer occurs in the bones, pain may occur in the affected region. Bone pain may also occur when the cancer affects the eyes. Symptoms may also include feeling tired, feeling as if one has not had enough sleep, or feeling depressed.
In a recent study, findings of this study suggest that current management practices are unlikely to lead to cure. Therefore a more radical approach, such as complete resection of the lesion, will probably be most effective in inducing cures in this disease, and in minimizing the chance of recurrence.
At the level of a cellular or cellularized entity, cancer may appear for a number of reasons, including genetic mutations to the genome, epigenetic lesions of the genomic information, or, perhaps, some form of epigenetic lesion within the RNA (transcriptional) information or other aspects of messenger RNA (mRNA). This model implies a cell-lineality as one of the reasons why cancer should be included with the other somatic (non-hermaphroditic) diseases. Other than this implication, it may also give some justification for excluding germ-cell cancer. In other words, it may be an alternative view of cancer, rather than a complementary one.
Different cancers have different symptoms. Often, the symptoms cannot be understood or diagnosed. Also, doctors often fail to recognise these symptoms while treating the cancer. Physicians should be aware of symptoms of cancer.
Pimasertib was well tolerated in people with a variety of cancers and, unlike other PI3K inhibitors, was associated with an improvement in HR-QOL among patients with solid tumors. Pimasertib has a potential role in cancer, particularly in combination with standard treatment, and warrants further investigation.
Pimasertib has a side effect profile similar to the other kinase inhibitors. The most common side effects were rash (18%), gastrointestinal: diarrhea (17%), dizziness (4%), dyspnoea (4%), fatigue (4%), and swelling (3%), and myalgia (3%). Serious adverse effects were observed in about 1,000–1,500 people, most of which were related to the underlying Bcr-Abl tyrosine kinase inhibitor action.
It is considered that pimasertib is generally well tolerated and that no serious side effects were observed in patients in this study and in other clinical studies involving high-dose treatment. In the interim analysis of the first Phase III trial, 4% of patients in the 50 mg arm experienced a serious adverse event, compared to 4.1% of patients in the 100 mg arm and 4.6% of people in the 300 mg arm (n = 491, 0.9%) Overall, the incidence of serious adverse events was not different among dose groups, including the 300 mg group: 1.1% (n = 45); 0.8% (n = 45); and 1.
the average age people have ever been diagnosed with cancer has risen in the last 100 years. Average age at diagnosis has risen over the lifetime of people in most developed country. This may be due to the improving healthcare throughout the life time. The rise in early diagnosis is not enough to offset the high percentage of people diagnosed with curable cancers. A rise in percentage of people with curable cancers may be due to increasing survival rates in curable cancers since diagnosis is earlier.
The most similar agent to pimasertib is MLN4924 which is now in phase II testing. Pimasertib is also now being tested in the ongoing E7021 trial with the goal of assessing the role that PI3K inhibitors may play in the treatment of breast cancer. It has also now been approved for further testing in a second phase I/II human trial.